Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.

Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O.

Front Oncol. 2018 May 22;8:156. doi: 10.3389/fonc.2018.00156. eCollection 2018. Review.

2.

Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.

Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

PMID:
29102648
3.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ; ICECaP Working Group.

J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.

PMID:
28796587
4.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. doi: 10.1016/j.ijrobp.2017.02.004. Epub 2017 Feb 12.

5.

Flexible modeling of the hazard rate and treatment effects in long-term survival studies.

Hagar Y, Dignam JJ, Dukic V.

Stat Methods Med Res. 2017 Oct;26(5):2455-2480. doi: 10.1177/0962280216688034. Epub 2017 Feb 2.

6.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG.

N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529.

7.

Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.

Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):450-461. doi: 10.1016/j.ijrobp.2016.10.042. Epub 2016 Nov 8.

8.

Comparison of futility monitoring guidelines using completed phase III oncology trials.

Zhang Q, Freidlin B, Korn EL, Halabi S, Mandrekar S, Dignam JJ.

Clin Trials. 2017 Feb;14(1):48-58. doi: 10.1177/1740774516666502. Epub 2016 Sep 22.

9.

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM.

J Clin Oncol. 2016 Jul 10;34(20):2325-32. doi: 10.1200/JCO.2016.67.0448. Epub 2016 Apr 4.

10.

Building firm foundations for therapy development.

Dignam JJ, Karrison TG.

J Natl Cancer Inst. 2015 Feb 20;107(3). pii: djv016. doi: 10.1093/jnci/djv016. Print 2015 Mar. No abstract available.

PMID:
25710961
11.

Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.

Wang M, Dignam JJ, Won M, Curran W, Mehta M, Gilbert MR.

Neuro Oncol. 2015 Jul;17(7):999-1006. doi: 10.1093/neuonc/nov009. Epub 2015 Feb 16.

12.

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM.

J Clin Oncol. 2015 Feb 1;33(4):332-9. doi: 10.1200/JCO.2014.58.0662. Epub 2014 Dec 22.

13.

Assessing treatment benefit with competing risks not affected by the randomized treatment.

Korn EL, Dignam JJ, Freidlin B.

Stat Med. 2015 Jan 30;34(2):265-80. doi: 10.1002/sim.6353. Epub 2014 Nov 3.

14.

A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.

Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY.

Clin Cancer Res. 2014 Dec 15;20(24):6379-88. doi: 10.1158/1078-0432.CCR-14-0075. Epub 2014 Oct 7.

15.

Bayesian approach for flexible modeling of semicompeting risks data.

Han B, Yu M, Dignam JJ, Rathouz PJ.

Stat Med. 2014 Dec 20;33(29):5111-25. doi: 10.1002/sim.6313. Epub 2014 Oct 2.

16.

Multiple imputation methods for nonparametric inference on cumulative incidence with missing cause of failure.

Lee M, Dignam JJ, Han J.

Stat Med. 2014 Nov 20;33(26):4605-26. doi: 10.1002/sim.6258. Epub 2014 Jul 4.

17.

Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation.

Sène M, Taylor JM, Dignam JJ, Jacqmin-Gadda H, Proust-Lima C.

Stat Methods Med Res. 2016 Dec;25(6):2972-2991. Epub 2014 May 20.

18.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP.

N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.

19.

Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.

Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D.

J Natl Cancer Inst. 2013 Sep 18;105(18):1365-72. doi: 10.1093/jnci/djt207. Epub 2013 Sep 3.

20.

Prevention of colorectal cancer and dietary management.

Hou N, Huo D, Dignam JJ.

Chin Clin Oncol. 2013 Jun;2(2):13. doi: 10.3978/j.issn.2304-3865.2013.04.03.

21.

Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.

Labby ZE, Armato SG 3rd, Dignam JJ, Straus C, Kindler HL, Nowak AK.

J Thorac Oncol. 2013 Apr;8(4):478-86. doi: 10.1097/JTO.0b013e31828354c8.

22.

NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ Jr, Bentzen SM, Okunieff P, Coleman CN, Dicker AP.

J Natl Cancer Inst. 2013 Jan 2;105(1):11-24. doi: 10.1093/jnci/djs472. Epub 2012 Dec 10.

23.

Integrated phase II/III clinical trials in oncology: a case study.

Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S.

Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22. Review.

PMID:
23180870
24.

Disease volumes as a marker for patient response in malignant pleural mesothelioma.

Labby ZE, Nowak AK, Dignam JJ, Straus C, Kindler HL, Armato SG 3rd.

Ann Oncol. 2013 Apr;24(4):999-1005. doi: 10.1093/annonc/mds535. Epub 2012 Nov 8.

25.

Optimization of response classification criteria for patients with malignant pleural mesothelioma.

Labby ZE, Armato SG 3rd, Kindler HL, Dignam JJ, Hasani A, Nowak AK.

J Thorac Oncol. 2012 Nov;7(11):1728-34. doi: 10.1097/JTO.0b013e318269fe21.

26.

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N.

J Clin Oncol. 2012 Nov 10;30(32):3960-6. doi: 10.1200/JCO.2011.40.8369. Epub 2012 Oct 1.

27.

A nomogram for individualized estimation of survival among patients with brain metastasis.

Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M, Kattan MW.

Neuro Oncol. 2012 Jul;14(7):910-8. doi: 10.1093/neuonc/nos087. Epub 2012 Apr 27.

28.

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH; American Society of Clinical Oncology.

J Clin Oncol. 2012 May 1;30(13):1553-61. doi: 10.1200/JCO.2011.39.9436. Epub 2012 Apr 2. Review.

PMID:
22473167
29.

Race and the prognostic influence of p53 in women with breast cancer.

Dookeran KA, Dignam JJ, Holloway N, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2012 Jul;19(7):2334-44. doi: 10.1245/s10434-011-1934-6. Epub 2012 Mar 21.

30.

Diffusing capacity predicts long-term survival after lung resection for cancer.

Ferguson MK, Dignam JJ, Siddique J, Vigneswaran WT, Celauro AD.

Eur J Cardiothorac Surg. 2012 May;41(5):e81-6. doi: 10.1093/ejcts/ezs049. Epub 2012 Feb 24.

31.

The use and interpretation of competing risks regression models.

Dignam JJ, Zhang Q, Kocherginsky M.

Clin Cancer Res. 2012 Apr 15;18(8):2301-8. doi: 10.1158/1078-0432.CCR-11-2097. Epub 2012 Jan 26.

32.

Multiple imputation methods for inference on cumulative incidence with missing cause of failure.

Lee M, Cronin KA, Gail MH, Dignam JJ, Feuer EJ.

Biom J. 2011 Nov;53(6):974-93. doi: 10.1002/bimj.201000175. Epub 2011 Oct 26.

PMID:
22028204
33.

Some additional thoughts on time-varying treatment effects in breast cancer.

Dignam JJ.

J Clin Oncol. 2011 Nov 20;29(33):4469-70; author reply 4470. doi: 10.1200/JCO.2011.37.8166. Epub 2011 Oct 24. No abstract available.

PMID:
22025147
34.

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group.

J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. doi: 10.1093/jnci/djr310. Epub 2011 Oct 12.

35.

Patterns of missing mini mental status exam (MMSE) in radiation therapy oncology group (RTOG) brain cancer trials.

Bae K, Bruner DW, Baek S, Movsas B, Corn BW, Dignam JJ.

J Neurooncol. 2011 Nov;105(2):383-95. doi: 10.1007/s11060-011-0603-8. Epub 2011 May 21.

PMID:
21603964
36.

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N.

J Natl Cancer Inst. 2011 Mar 16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11.

37.

Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003).

Chung CH, Dignam JJ, Hammond ME, Klimowicz AC, Petrillo SK, Magliocco A, Jordan R, Trotti A, Spencer S, Cooper JS, Le QT, Ang KK.

J Clin Oncol. 2011 Apr 1;29(10):1326-34. doi: 10.1200/JCO.2010.32.3295. Epub 2011 Feb 28.

38.

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE.

J Clin Oncol. 2010 Jul 10;28(20):3336-43. doi: 10.1200/JCO.2009.27.0397. Epub 2010 May 24.

39.

Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.

Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O'Connell MJ, Wolmark N, Wang SJ.

J Clin Oncol. 2010 May 20;28(15):2544-8. doi: 10.1200/JCO.2009.23.0573. Epub 2010 Apr 20.

40.

Population-based survival-cure analysis of ER-negative breast cancer.

Huang L, Johnson KA, Mariotto AB, Dignam JJ, Feuer EJ.

Breast Cancer Res Treat. 2010 Aug;123(1):257-64. doi: 10.1007/s10549-010-0752-z. Epub 2010 Feb 4.

PMID:
20130982
41.

Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group.

Dignam JJ.

J Natl Cancer Inst. 2010 Feb 24;102(4):279-80; author reply 280-2. doi: 10.1093/jnci/djp505. Epub 2010 Jan 14. No abstract available.

PMID:
20075368
42.

p53 as a marker of prognosis in African-American women with breast cancer.

Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2010 May;17(5):1398-405. doi: 10.1245/s10434-009-0889-3. Epub 2010 Jan 5.

PMID:
20049641
43.

Predictors of competing mortality in advanced head and neck cancer.

Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR.

J Clin Oncol. 2010 Jan 1;28(1):15-20. doi: 10.1200/JCO.2008.20.9288. Epub 2009 Nov 23.

PMID:
19933920
44.

Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts.

Dignam JJ, Huang L, Ries L, Reichman M, Mariotto A, Feuer E.

Cancer. 2009 Nov 15;115(22):5272-83. doi: 10.1002/cncr.24617.

45.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N.

J Clin Oncol. 2009 May 20;27(15):2466-73. doi: 10.1200/JCO.2008.19.8424. Epub 2009 Apr 6.

46.

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.

Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N.

Breast Cancer Res Treat. 2009 Aug;116(3):595-602. doi: 10.1007/s10549-008-0200-5. Epub 2008 Oct 2.

47.

Choice and interpretation of statistical tests used when competing risks are present.

Dignam JJ, Kocherginsky MN.

J Clin Oncol. 2008 Aug 20;26(24):4027-34. doi: 10.1200/JCO.2007.12.9866.

48.

Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment.

Hall MJ, Dignam JJ, Olopade OI.

J Genet Couns. 2008 Aug;17(4):365-72. doi: 10.1007/s10897-008-9154-3. Epub 2008 Jun 25.

49.

Comments on: Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Time-varying pattern of recurrence risk for Chinese breast cancer patients.

Dignam JJ, Dukic VM.

Breast Cancer Res Treat. 2009 Jul;116(1):209-10. doi: 10.1007/s10549-008-0092-4. Epub 2008 Jun 21. No abstract available.

PMID:
18568398
50.

Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers.

Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, Artioli G, Dudlicek L, Olopade OI.

Genet Med. 2008 Mar;10(3):161-166. doi: 10.1097/GIM.0b013e318163487d.

Supplemental Content

Loading ...
Support Center